Highest-materiality recent filing
Climb Bio Announces Positive Initial Phase 1b Data for Budoprutug in Immune Thrombocytopenia
Phase 1b enrolled 15 patients at 250 mg (n=6) and 500 mg (n=9) doses, median follow-up 38 and 12 weeks respectively.
Climb Bio reports positive Phase 1 safety data for CLYM116; plans Phase 2 in IgAN in Q3 2026
Translational PK/PD model from NHP data projects dose-dependent IgA suppression, suggesting less-frequent dosing.
Climb Bio reports Q1 2026 cash of $146.3M; $110M private placement closed April 29
R&D expense $9.4M vs $17.3M YoY (incl. $9M CLYM116 upfront in prior year); G&A $5.8M.
Climb Bio reports positive SC formulation data; ITP data June 2026, pMN/SLE Q4 2026
Topline Phase 1 SC data: robust B-cell depletion similar to IV; generally safe and well-tolerated.
Climb Bio raises $110M in private placement of common stock and pre-funded warrants
Gross proceeds of ~$110M from 9.481M shares at $9.50 and 2.106M pre-funded warrants at $9.4999 each.
Climb Bio reports Q4/FY2025 results; cash $160.7M; pipeline trials on track with data in 2026
Cash, cash equivalents, and marketable securities $160.7M as of Dec 31, 2025; expected runway into 2028.
Climb Bio updates on budoprutug and CLYM116 trials; cash runway into 2028
First patient dosed in PrisMN Phase 2 trial of budoprutug for primary membranous nephropathy (Nov 2025).
Climb Bio sues Alumis to avoid $3M milestone payment, disputes 'Product' definition under APA
Filed complaint in Delaware Superior Court seeking declaratory judgment that budoprutug is not a 'Product' under the APA.
Climb Bio exchanges 20.44M shares for pre-funded warrants; RA Capital voting capped at 33%
Exchanged 20,440,000 shares for pre-funded warrants with $0.0001 exercise price via Section 3(a)(9) exemption.
Climb Bio Q3 2025 cash $175.8M; pipeline advances with budoprutug and CLYM116 trials
Cash and equivalents $175.8M as of Sep 30, 2025; runway expected through 2027.
Climb Bio reports long-term Phase 1b data for budoprutug; up to 3-year proteinuria control
Abstract published for budoprutug (anti-CD19 mAb) showing durable proteinuria control up to 3 years in four PMN patients.
Climb Bio appoints Susan Altschuller as CFO, grants 600,000 stock options
Appointed Susan Altschuller, Ph.D., MBA, as CFO and Treasurer effective Oct 1, 2025; previously CFO at Cerevel and ImmunoGen.
In nonhuman primate study, CLYM116 showed ~2-3 times longer half-life and deeper IgA reduction vs sibeprenlimab at 6 mg/kg.
Climb Bio Q2 cash $187.4M, R&D $6.6M; budoprutug trials underway; new CMO
Cash and marketable securities $187.4M as of June 30, 2025; cash runway expected through 2027.
COO Brett Kaplan departs Climb Bio; CEO Aoife Brennan named interim PFO
Brett Kaplan, COO and principal financial officer, separated mutually on May 23, 2025.
Climb Bio reports Q4/FY2024 results, cash $212.5M through 2027; launches $22.35M ATM offering
Entered ATM equity offering of up to $22.35M via Oppenheimer; 3% commission; proceeds to support pipeline.
Climb Bio licenses MIL116 antibodies from Mabworks; reports $212.9M cash, runway through 2027
Upfront $9M to Mabworks; up to $30M development/regulatory milestones for first indication.
Climb Bio Q3 net loss $8.9M; cash $217.9M through 2027; FDA IND cleared for SLE trial
Net loss $8.9M for Q3 2024 vs $4.0M Q3 2023; R&D expenses $6.2M, G&A $5.5M.
Climb Bio outlines budoprutug development strategy; Phase 1b pMN data shows 60% remission
Approximately $218M cash at Sept 30, 2024; expected to fund operations through 2027.
Eliem Therapeutics CSO departs, CFO role changed, Executive Chairman resigns amid strategic pivot
Valerie Morisset, EVP R&D and CSO, separated August 23; settlement provides 18 months base salary, pro rata bonus, accelerated equity vesting.
Eliem Therapeutics Q2 net loss $54.9M; completed Tenet Medicines acquisition and $120M financing
Completed acquisition of Tenet Medicines and concurrent $120M private placement in June 2024.
Eliem closes acquisition of Tenet Medicines, gains TNT119 autoimmune drug, raises $120M PIPE
Acquisition of Tenet closed June 27; 5,560,047 Eliem shares issued to Tenet equityholders.
Shareholders approve Eliem-Tenet merger; closing expected June 27, 2024
Share Issuance Proposal passed: 26,311,239 for, 3,253 against; disinterested approval 12,655,083 for.
Eliem to acquire Tenet Medicines in stock deal; raises $120M PIPE at $3.84/share
Eliem (ELYM) acquires Tenet via merger; Tenet holders get 15.4% of combined co. stock.
Eliem receives non-binding term sheet to acquire biotech Tango for $20M in stock
RA Capital owns ~47.5% of Eliem and majority of Tango; special committee oversees strategic review.
Eliem halts Kv7 program, explores strategic alternatives including sale or merger
Halts further development of Kv7 program; shifts focus to maximizing shareholder value.
Erin Lavelle resigned as EVP, COO, and CFO effective March 10, 2023.
Eliem restructures, pauses ETX-155, focuses on Kv7 program, extends cash runway into 2027
Corporate reorganization: pause ETX-155 (GABA A PAM) development, focus on Kv7 program lead ETX-123; workforce reduction ~55% in H1 2023.
Eliem Therapeutics pauses ETX-155, cuts workforce 55%, CEO and CFO depart; cash $123.6M
Pauses development of ETX-155 (Phase 2-ready for MDD) to focus on preclinical Kv7.2/3 program (ETX-123).
Eliem Therapeutics Q3 net loss $9.7M, cash $129.6M; ETX-155 Phase 2a MDD trial to start Q1 2023
Net loss of $9.7M for Q3 2022 (vs. $9.6M Q3 2021); R&D expenses $4.3M, G&A $4.5M.
Eliem Therapeutics ETX-155 update; Phase 2a MDD on track for Q1 2023; cash $129.8M
Cash, cash equivalents and investments of $129.8M as of Sept 30, 2022 (includes $6.2M tax reimbursements); funds operations into 2025.
Eliem Therapeutics Q2 net loss $14.6M; discontinues ETX-810 Phase 2a after failure
Net loss of $14.6M for Q2 2022 vs $8.7M in Q2 2021; cash, equivalents, securities $134.7M.
Lower-than-expected ETX-155 exposure in Phase 1b photosensitive epilepsy trial attributed to CMC batch inconsistencies.
Eliem Q1 net loss $13.2M; ETX-810 fails DPNP trial; ETX-155 data inconclusive; LSRP data Q3
Net loss of $13.2M in Q1 2022 vs $18.6M in Q1 2021; cash $149.9M, funded through at least 2023.
The Board of Directors (the “Board”) of Climb Bio, Inc. (the “Company”) appointed Cindy Driscoll as Senior Vice President, Finance of the Company and designated her as the Company’s principal financial officer and principal accounting officer, effective as of June 17, 2025
On May 23, 2025, Climb Bio, Inc. (the “Company”) and Brett Kaplan, M.D., its Chief Operating Officer and principal financial officer, mutually agreed that Dr. Kaplan would separate from the Company, effective May 23, 2025
On the Separation Date, the Board of Directors of the Company appointed Aoife Brennan as the Company’s interim principal financial officer, effective as of May 24, 2025.
Simon Tate notified Climb Bio, Inc. (the “Company”) of his decision to resign as a member of the Company’s board of directors
Mr. Cumbo was elected to serve with a term expiring at the Company’s 2026 annual meeting of stockholders and thereafter until his successor has been duly appointed and qualified or until his earlier death, resignation or removal.
Ms. Drapkin was elected to serve with a term expiring at the Company’s 2027 annual meeting of stockholders and thereafter until her successor has been duly appointed and qualified or until her earlier death, resignation or removal.
Adam Rosenberg notified the Company that he does not intend to seek re-election as a member of the Board when his current term ends at the Company’s 2025 annual meeting of stockholders.
On August 26, 2024, the Board of Directors of the Company (the “Board”) appointed Brett Kaplan, the Company’s Chief Operating Officer, to serve as principal financial officer.
The appointment was made in connection with Andrew Levin’s resignation from his role as Executive Chairman of the Company. Dr. Levin continues to serve as a director of the Company and was appointed Chairman of the Board in connection with his resignation as Executive Chairman.
On August 26, 2024, Eliem Therapeutics, Inc. (the “Company”) announced that its board of directors (the “Board”) had appointed Brett Kaplan, M.D., as Chief Operating Officer of the Company, effective August 26, 2024
the Board elected Stephen Thomas, Ph.D., the then-Chief Executive Officer of Tenet, to serve as a director on the Board, subject to and contingent and effective upon the closing of the Acquisition, from the Effective Date until the Company’s 2025 annual meeting of stockholders and thereafter until his successor has been duly elected and qualified or until his earlier death, resignation or removal.
In addition, Dr. Brennan was elected as a director to serve on the Board from the Effective Date until the Company’s 2027 annual meeting of stockholders and thereafter until her successor has been duly elected and qualified or until her earlier death, resignation or removal.
Max materiality 0.90 · Median 0.65 · Most common event other_material